<DOC>
	<DOCNO>NCT01513551</DOCNO>
	<brief_summary>The purpose study see investigational vaccine Streptococcus pneumonia disease ( V114 ) comparable safety , tolerability , antibody response Pneumococcal Polysaccharide Vaccine ( Pneumovax 23 ) 13-valent Pneumococcal Conjugate Vaccine ( Prevnar 13 ) administer healthy adult 50 year age old .</brief_summary>
	<brief_title>A Study Compare Safety Immunogenicity Pneumococcal Conjugate Vaccines Healthy Volunteers ( V114-002 )</brief_title>
	<detailed_description />
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Without fever 72 hour prior vaccination Prior receipt pneumococcal polysaccharide vaccine pneumococcal conjugate vaccine Known suspect immunocompromised Functional anatomic asplenia History autoimmune disease Evidence dementia cognitive impairment Use immunosuppressive therapy Received license nonlive vaccine administer within 14 day prior receipt study vaccine schedule receive license vaccine within 30 day follow receipt study vaccine Received license live virus vaccine within 30 day prior receipt study vaccine schedule receive license vaccine within 30 day receipt study vaccine Received vaccine contain diphtheria toxoid within 6 month prior receipt study vaccine Received blood transfusion blood product within 6 month receipt study vaccine schedule receive blood transfusion blood product within 30 day receipt study vaccine History invasive pneumococcal disease know history culturepositive pneumococcal disease Received antibiotic therapy acute illness within 72 hour receipt study vaccine</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>